Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Dual-time-point [<sup>18</sup>F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.

EJNMMI research·2026
Same author

Mass spectrometry-based proteomics delivers in-depth proteome profiling of FFPE lung cancer biopsies from single glass slides.

NPJ precision oncology·2026
Same author

From documentation to discovery: clinicians' perspectives on the generation, usability and standardization of real-world data.

International journal of medical informatics·2026
Same author

DNA methylation and expression of MAPRE3 affect overall survival of early-stage non-small cell lung cancer patients.

Molecular oncology·2026
Same author

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC.

Future oncology (London, England)·2026

Related Experiment Video

Updated: May 22, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

[Mutation testing for non-small-cell lung cancer].

Odd Terje Brustugun1, Åslaug Helland, Lars Fjellbirkeland

  • 1Avdeling for kreftbehandling, Oslo universitetssykehus, Radiumhospitalet, Norway. otr@ous-hf.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|May 8, 2012
PubMed
Summary
This summary is machine-generated.

EGFR mutation testing in non-small cell lung cancer identified mutations in 11.6% of patients. Testing is recommended for all non-small cell lung cancer patients due to high mutation frequency.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Experiment Videos

Last Updated: May 22, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • Epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent a novel treatment for non-small cell lung cancer (NSCLC).
  • The Norwegian Lung Cancer Group advocates for EGFR mutation testing in NSCLC patients.
  • This study details Norway's experience with EGFR mutation testing introduced in 2010.

Purpose of the Study:

  • To evaluate the initial experience and outcomes of EGFR mutation testing in Norway.
  • To assess the frequency and characteristics of EGFR mutations in Norwegian NSCLC patients.

Main Methods:

  • Data collected from molecular-pathology laboratories at four Norwegian university hospitals (May 2010-May 2011).
  • Included patient numbers, gender distribution, histopathological data, and EGFR mutation analysis results.
  • 1,058 lung cancer patients were tested for EGFR gene mutations.

Main Results:

  • A total of 1,058 NSCLC patients underwent EGFR mutation testing, representing approximately 50% of diagnosed cases.
  • EGFR mutations were detected in 11.6% of patients (123 out of 1,058).
  • Mutation positivity was significantly higher in women (17.6%) than men (6.3%) and lower in squamous cell carcinoma (3.0%) compared to other subtypes (12.9%).

Conclusions:

  • The study found a notable frequency of EGFR mutations in Norwegian NSCLC patients.
  • A significant proportion of mutations were observed in non-squamous cell carcinoma subtypes.
  • Continued EGFR mutation testing for all NSCLC patients is recommended based on these findings.